0000899243-19-016722.txt : 20190612
0000899243-19-016722.hdr.sgml : 20190612
20190612210052
ACCESSION NUMBER: 0000899243-19-016722
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190610
FILED AS OF DATE: 20190612
DATE AS OF CHANGE: 20190612
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kemmerly David L
CENTRAL INDEX KEY: 0001673554
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24260
FILM NUMBER: 19894751
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMEDISYS INC
CENTRAL INDEX KEY: 0000896262
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082]
IRS NUMBER: 113131700
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
BUSINESS PHONE: 2252922031
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
FORMER COMPANY:
FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP
DATE OF NAME CHANGE: 19940819
FORMER COMPANY:
FORMER CONFORMED NAME: M&N CAPITAL CORP
DATE OF NAME CHANGE: 19930125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-06-10
0
0000896262
AMEDISYS INC
AMED
0001673554
Kemmerly David L
3854 AMERICAN WAY, SUITE A
BATON ROUGE
LA
70816
0
1
0
0
See Remarks
Common Stock
2019-06-10
4
M
0
1875
27.35
A
17107
D
Common Stock
2019-06-10
4
M
0
3125
27.35
A
20232
D
Common Stock
2019-06-10
4
M
0
3125
27.35
A
23357
D
Common Stock
2019-06-10
4
S
0
8125
117.77
D
15232
D
Common Stock
445
I
Through 401(k) Plan
Stock Option (right to buy)
27.35
2019-06-10
4
M
0
1875
0.00
D
2025-05-01
Common Stock
1875
0
D
Stock Option (right to buy)
27.35
2019-06-10
4
M
0
3125
0.00
D
2025-05-01
Common Stock
3125
3125
D
Stock Option (right to buy)
27.35
2019-06-10
4
M
0
3125
0.00
D
2025-05-01
Common Stock
3125
6250
D
The total amount of shares beneficially owned includes 219 shares held in an employee stock purchase plan account.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.46 to $118.26, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The information in this report is based on a plan statement dated as of March 31, 2019.
On May 1, 2015, the reporting person was granted an option to purchase 37,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2016 were met, resulting in vesting of the option as to 9,375 shares (the "2016 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2016 Tranche Options vested on May 1, 2017, one-third of the 2016 Tranche Options vested on May 1, 2018 and one-third of the 2016 Tranche Options vested on May 1, 2019. After the transaction being reported herein, the reporting person has exercised all of the 2016 Tranche Options.
On May 1, 2015, the reporting person was granted an option to purchase 37,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2017 were met, resulting in vesting of the option as to 9,375 shares (the "2017 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2017 Tranche Options vested on May 1, 2018, one-third of the 2017 Tranche Options vested on May 1, 2019 and one-third of the 2017 Tranche Options will vest on May 1, 2020, assuming the reporting person remains continuously employed by the Issuer on such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the options. After the transaction being reported herein, the reporting person has exercised 6,250 of the 2017 Tranche Options.
On May 1, 2015, the reporting person was granted an option to purchase 37,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2018 were met, resulting in vesting of the option as to 9,375 shares (the "2018 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2018 Tranche Options vested on May 1, 2019, and two-thirds of the 2018 Tranche Options will vest on May 1, 2020, assuming the reporting person remains continuously employed by the Issuer on such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the options. After the transaction being reported herein, the reporting person has exercised 3,125 of the 2018 Tranche Options.
General Counsel and Senior Vice President of Government Affairs
/s/ Jennifer R. Guckert, pursuant to a power of attorney
2019-06-12